Although crystal-induced arthritis is still a consideration, gout in the hip is usually a very rare and late manifestation of longstanding gouty arthritis
Acute gouty arthritis
without urate crystals identified on initial examination of synovial fluid: report on nine patients.
Global Markets Direct's, 'Gouty Arthritis
(Gout) - Pipeline Review, H1 2012', provides an overview of the Gouty Arthritis
(Gout) therapeutic pipeline.
01 Group III Septic or Severe Inflammatory Group a.
Novartis announced today that the European Commission (EC) has approved llaris (canakinumab, ACZ885) in the treatment of patients with acute gouty arthritis
who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options.
Spontaneous resolution of acute gouty arthritis
is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3.
The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis
Safety concerns have likely scuttled approval for now of the biologic canakinumab for management of flares of gouty arthritis
If the findings are validated in larger investigations, the drug, rilonacept, may offer much-needed relief to patients with severe gouty arthritis
who are refractory to other therapies, Dr.
Abstract: Although colchicine is a commonly used medication in patients with gouty arthritis
and various multisystem disorders, its safety margin in therapeutic use is not well understood.
GlobalData's clinical trial report, Gouty Arthritis
(Gout) Global Clinical Trials Review, H2, 2011" provides data on the Gouty Arthritis
(Gout) clinical trial scenario.
Novartis AG stated that Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency gave its opinion in favor of the use of llaris in the treatment of patients with acute gouty arthritis
who suffer frequent attacks, and whose symptoms should not be managed with treatment options.